503 results on '"Schellens, J.H.M."'
Search Results
2. Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling
3. Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry
4. Ultra-sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine in human plasma for a microdose clinical trial
5. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine
6. Abstract CT185: First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521
7. Inherent formulation issues of kinase inhibitors
8. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry
9. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies
10. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography–tandem mass spectrometry
11. Validation of high-performance liquid chromatography–tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4′‑des-methyl and cephalotaxine metabolites in human plasma and urine
12. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry
13. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II
14. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel
15. Selection of oncology medicines in low- and middle-income countries
16. 829P A proof of concept study of sequential treatment with the HDAC inhibitor vorinostat plus BRAF and MEK inhibitors in BRAFV600 mutated melanoma
17. 70P Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study
18. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography–tandem mass spectrometry
19. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors
20. 596P Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study
21. Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study
22. Prevention of fluoropyrimidine toxicity: do we still have to try our patientʼs luck?
23. Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine
24. Development and validation of LC–MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices
25. Approaching tumour therapy beyond platinum drugs: Status of the art and perspectives of ruthenium drug candidates
26. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
27. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
28. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
29. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques
30. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
31. Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages
32. Development and validation of a liquid chromatography–tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5- b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice
33. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: A review
34. Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy
35. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry
36. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry
37. Trabectedin (Yondelis[TM], formerly ET-743), a mass balance study in patients with advanced cancer
38. Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology
39. Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies
40. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography–tandem mass spectrometry
41. A paradigm shift in early drug development: individualizing to more patient benefit
42. The Accumulation of Topotecan in 9L Glioma and in Brain Parenchyma with and without Dexamethasone Administration
43. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose
44. Hepatotoxicity and metabolism of trabectedin: a literature review
45. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis
46. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives
47. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine
48. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma
49. Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non–Small-Cell Lung Cancer
50. Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.